Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifampicin and pyrazinamide in shortened treatment of mild-to-moderate tuberculosis
2024-518772-32-00Phase 2Authorised
- Sponsor
- Region Östergötland
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rifampicin and pyrazinamide in Tuberculosis (TB) (2 arms), sponsored by Region Östergötland. Primary endpoints: AUC0-24h for high-dose rifampicin on day 1 and AUC0-24h for high-dose rifampicin at week 2. Planned start Oct 2024; status: authorised.
02
Drugs
rifampicinpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on 2024-518772-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518772-32-00.